SCHEMBL4680681

SCHEMBL4680681

O=C(O)C(O)=CC(=O)c1ccc(Cc2ccccc2)[nH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.36
KDM5A P29375 2/20 0.35
KDM4C Q9H3R0 2/20 0.35
KDM5B Q9UGL1 2/20 0.35
KDM4A O75164 1/20 0.35
DAO P14920 1/20 0.34
AOC3 Q16853 1/20 0.34
IDO1 P14902 1/20 0.34
PLA2G10 O15496 1/20 0.33
PLA2G2A P14555 1/20 0.33
LMNA P02545 1/20 0.33
ITK Q08881 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
CALM1 P0DP23 1/20 0.32
RNASEH1 O60930 1/20 0.32
PARP1 P09874 1/20 0.32
CAPN1 P07384 1/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4680678 1.00 HCAR2 (0.38) HCAR2SMN1; SMN2KDM5AKDM4CKDM5B
SCHEMBL4675725 0.87 HRH4 (0.36) SMN1; SMN2KDM5AKDM4CKDM5BKDM4A
SCHEMBL4676889 0.87 SRD5A2 (0.38) SMN1; SMN2DAOLMNA
SCHEMBL4670505 0.87 DAO (0.36) DAOLMNA
SCHEMBL4676715 0.87 ITGB1 (0.38) HRH3
SCHEMBL4676710 0.87 ITGB1 (0.38) HRH3
SCHEMBL4675726 0.87 HRH4 (0.36) SMN1; SMN2KDM5AKDM4CKDM5BKDM4A
SCHEMBL4670507 0.87 DAO (0.36) DAOLMNA
SCHEMBL4676895 0.87 SRD5A2 (0.38) SMN1; SMN2DAOLMNA
SCHEMBL4671283 0.85 HCAR2 (0.47) HCAR2KDM5AKDM4CKDM5BDAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HCAR2 276/4885SMN1; SMN2 4107/4885KDM5A 1534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.